Scilex Holding Teams with Endeavor Distribution.

PALO ALTO, Calif., June 20, 2024 — Scilex Holding Company (Nasdaq: SCLX), a forward-thinking company specializing in non-opioid pain management solutions, has recently entered into a non-exclusive distribution agreement with Endeavor Distribution LLC. Endeavor, known for its over a decade of sales excellence, will handle the national distribution and logistics for Scilex's current product lineup. This strategic move is aimed at enhancing the availability of Scilex’s non-opioid pain management products to both new and existing specialized customers across the country.

Endeavor, based in Oklahoma, brings vast experience in logistics, warehousing, manufacturing, and customer service. Their expertise will be instrumental in providing top-notch pick and pack fulfillment and other essential warehouse services for Scilex’s clients.

Jaisim Shah, CEO and President of Scilex, expressed confidence in this partnership, noting that the commercialization of Scilex’s three non-opioid products is progressing as planned. Shah anticipates that product growth will accelerate through the current year and into 2024. He emphasized the importance of expanding logistics and distribution capabilities to support the company’s aggressive product launch strategy. The partnership with Endeavor is seen as a pivotal step in ensuring a successful introduction of Scilex's products to specialized point-of-care customers.

Scilex Holding Company, headquartered in Palo Alto, California, focuses on developing and commercializing non-opioid therapies for acute and chronic pain. The company's commercial products include ZTlido® (lidocaine topical system) 1.8%, ELYXYB®, and Gloperba®.

ZTlido® is a prescription lidocaine topical product approved by the FDA to relieve neuropathic pain associated with postherpetic neuralgia, a type of nerve pain following shingles. ELYXYB® is an FDA-approved ready-to-use oral solution for the acute treatment of migraines in adults, making it a potential first-line treatment for this condition. Gloperba® is the first and only liquid oral colchicine formulation indicated for the prophylaxis of painful gout flares in adults.

In addition to these marketed products, Scilex has three product candidates in development. SP-102 (SEMDEXA™) is a novel viscous gel formulation of dexamethasone sodium phosphate for epidural injections to treat sciatica. This product has completed Phase 3 trials and received Fast Track status from the FDA in 2017. SP-103 is a next-generation, triple-strength formulation of ZTlido for chronic neck pain, which has recently completed Phase 2 trials for low back pain and also has Fast Track status from the FDA. Lastly, SP-104 is a low-dose, delayed-release naltrexone hydrochloride capsule being developed for fibromyalgia, with Phase 1 trials completed in 2022.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!